LITERATURE
原始候选快照
v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。
| 论文 | 标识 | 日期 | 入排置信度 | 入排依据 | KM 状态 |
|---|---|---|---|---|---|
| Survival Odds to Minimize Risk Heterogeneity Bias in Heart Failure Trials: Application to Dapagliflozin.Circ Heart Fail | PMID 41170566PMC12704667 | 2025-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 已完成 |
| Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41175888无 PMCID | 2025-Dec | 0.96 | 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 | 无 KM 图 |
| The influence of body mass index on Tumor Treating Fields therapy in patients with metastatic non-small cell lung cancer: A post-hoc and simulation analysis from the phase III LUNAR study.Lung Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41187466无 PMCID | 2025-Dec | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 无 KM 图 |
| Targeted Oral Peptide Icotrokinra for Psoriasis Involving High-Impact Sites.NEJM EvidPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41191932无 PMCID | 2025-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Immune persistence and safety of the AS01E-adjuvanted respiratory syncytial virus prefusion F protein-based vaccine in adults 50-59 years of age, including at-increased-risk adults: A randomized controlled trial.Hum Vaccin Immunother已检查 4 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Figure 2:研究设计图;Figure 3:AI 判定为 flow diagram;Figure 4:AI 判定为 other。 | PMID 41194599PMC12599337 | 2025-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Radiotherapy plus Long-term Adjuvant Androgen Deprivation with a Luteinizing Hormone-releasing Hormone Antagonist Versus Agonist in Patients with Very High-risk Localized or Locally Advanced Prostate Cancer: The EORTC GUCG-1414 Phase 3 Randomized Trial.Eur Urol Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41206286无 PMCID | 2025-Dec | 0.80 | The study meets criteria for oncology, human, randomized, phase 3, drug intervention, and original result. However, it does not meet the 'time_to_event' criterion because the primary endpoint was changed to a binary response (PSA nadir) and the PFS endpoint, while mentioned, is not presented with Kaplan-Meier data or a hazard ratio suitable for digitization. | 无 KM 图 |
| The Effectiveness of Plecanatide for Treating Constipation and Bloating in Patients Aged 18 to 40 Years With Irritable Bowel Syndrome: Utilization of a New Composite Trisymptom Endpoint.J Gastroenterol Hepatol已检查 2 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 other;FIGURE 2:AI 判定为 other。 | PMID 41214272PMC12666612 | 2025-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Efficacy and safety of iclepertin for cognitive impairment associated with schizophrenia (CONNEX programme): results from three phase 3 randomised controlled trials.Lancet PsychiatryPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41233083无 PMCID | 2025-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Frequent productive cough in COPD relates to exacerbation risk and treatment benefit from budesonide/glycopyrrolate/formoterol fumarate: a post hoc analysis of KRONOS.Respir MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41237914无 PMCID | 2025-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Safety and non-inferiority of multidose and single-dose vial formulations of EuTCV Vi-CRM197 versus Typbar TCV in healthy participants in Kenya and Senegal: a multicentre, observer-blind, randomised, phase 3 study.Lancet Glob HealthPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41240950无 PMCID | 2025-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Early onset, maintenance of effect, and day-/night-time findings following fezolinetant treatment for moderate to severe vasomotor symptoms associated with menopause: A pooled phase 3 analysis.MaturitasPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41259888无 PMCID | 2025-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer: 5-year extended follow-up for the randomized phase III KEYNOTE-590 study.ESMO Open | PMID 41259897PMC12670541 | 2025-Dec | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Matching-adjusted indirect comparison of kidney function in patients with immunoglobulin A nephropathy treated with nefecon or sparsentan.J Comp Eff Res入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 41263371PMC12679650 | 2025-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Bevacizumab plus chemotherapy versus chemotherapy in untreated advanced non-squamous non-small-cell lung cancer patients with brain metastases (BAP BRAIN): an open-label, randomized, multicenter, phase III study.ESMO Open | PMID 41270700PMC12670085 | 2025-Dec | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Tumor-Informed ctDNA in Guiding First-Line Immunochemotherapy in Advanced Non-Small Cell Lung Cancers.Adv Sci (Weinh) | PMID 41287887PMC12752622 | 2025-Dec | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 部分完成 |
| Efficacy and safety of Ivarmacitinib in moderate-to-severe atopic dermatitis patients with or without previous systemic treatments: a post-hoc analysis of a phase III trial.J Dermatolog Treat入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 41288059无 PMCID | 2025-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| PROMENADE: pembrolizumab for early ER-low/HER2-negative breast cancer, real-world French cohort.ESMO Open入排证据不足,等待复核:The record is a retrospective real-world cohort study reporting pathological complete response (pCR) rates, not a randomized trial with a primary/key secondary time-to-event efficacy endpoint. It does not meet the inclusion criteria for a drug-containing randomized trial with a time-to-event endpoint. | PMID 41297161PMC12689199 | 2025-Dec | 0.45 | The record is a retrospective real-world cohort study reporting pathological complete response (pCR) rates, not a randomized trial with a primary/key secondary time-to-event efficacy endpoint. It does not meet the inclusion criteria for a drug-containing randomized trial with a time-to-event endpoint. | 无 KM 图 |
| Safety and efficacy of tiragolumab, atezolizumab and chemotherapy for early-stage or PD-L1-positive advanced triple-negative breast cancer: a phase Ib study.ESMO OpenAI 判定该论文不进入自动 KM 提取:This is a phase Ib study, not a phase III trial. While it includes a randomized component in one cohort, it is an early-phase, open-label study. | PMID 41297162PMC12689193 | 2025-Dec | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 无 KM 图 |
| Maintained improvement of outcomes related to skin clearance, itch, sleep and quality of life with baricitinib in adults with moderate-to-severe Atopic Dermatitis who were treated for up to 200 weeks in a randomized trial.J Dermatolog TreatPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41306112无 PMCID | 2025-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations (FABULOUS): interim analysis of a multicentre, three-arm, open-label, randomised, phase 3 trial.Lancet Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41308673无 PMCID | 2025-Dec | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Metronomic capecitabine as extended adjuvant chemotherapy for early triple-negative breast cancer (SYSUCC-001): updated 10-year outcomes and post-hoc exploratory biomarker analysis from a randomised, phase 3 trial.Lancet Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41308674无 PMCID | 2025-Dec | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 无 KM 图 |
| Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study.Lancet Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41308676无 PMCID | 2025-Dec | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Efficacy and safety of Tan Yin Wan in preventing acute exacerbations of COPD: A multicenter, randomized, double-blind, placebo-controlled, phase Ⅳ clinical trial.Phytomedicine入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 41313848无 PMCID | 2025-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Efficacy and safety of a mosaic HIV-1 vaccine regimen in men who have sex with men and transgender individuals (HVTN 706/HPX3002/Mosaico): a global, randomised, double-blind, placebo-controlled, phase 3 trial.Lancet HIVPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41314741无 PMCID | 2025-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Therapeutic Modulation of IL-6/STAT-3 and Nitric Oxide by Fenofibrate in Patients With Ulcerative Colitis: A Randomized Controlled Pilot Study.Pharmacotherapy入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 41330887无 PMCID | 2025-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Evaluation of Weight Gain and Overall Survival of Men Versus Women With Advanced Non-Small Cell Lung Cancer.J Cachexia Sarcopenia Muscle入排复审未纳入:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | PMID 41332393PMC12673274 | 2025-Dec | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 无 KM 图 |
| A Phase 3 study to assess the safety and immunogenicity of a quadrivalent meningococcal conjugate vaccine (MenACYW-TT) co-administered with routine pediatric vaccines in healthy infants in the USA and Puerto Rico.Hum Vaccin Immunother已检查 7 张 PubMed Figure,均未识别为 KM 图:captionless-figure:AI 判定为 other;captionless-figure:AI 判定为 other;Figure 1:AI 判定为 other;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other;另有 2 张未列出。 | PMID 41337697PMC12688245 | 2025-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Radiomic signatures to estimate survival in patients with advanced hepatocellular carcinoma treated with sorafenib: Cancer and Leukemia Group B 80802 (Alliance).ESMO Open | PMID 41337859PMC12720083 | 2025-Dec | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Streptozotocin plus 5-fluorouracil followed by everolimus or the reverse sequence in patients with advanced pancreatic neuroendocrine tumors (SEQTOR-GETNE phase III study): a randomized clinical trial.ESMO Open | PMID 41337860PMC12720089 | 2025-Dec | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Association of SULT2A1 Locus With Abiraterone Clearance in the Alliance A031201: Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer.Clin Transl Sci疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:FIGURE 1:CONSORT/入组流程图;FIGURE 2:非 KM 图;FIGURE 3:非 KM 图。 | PMID 41346252PMC12678863 | 2025-Dec | 0.45 | The report describes a Phase III randomized trial (Alliance A031201) but is an analysis of genetic associations with drug clearance (pharmacokinetics). It does not report or focus on a primary/key secondary time-to-event efficacy endpoint such as OS or PFS. The study is therefore ineligible. | 无 KM 图 |
| No Effect of Immunogenicity on Pharmacokinetics, Efficacy, and Safety of the Oligonucleotide Telomerase Inhibitor Imetelstat in Lower-Risk Myelodysplastic Syndromes.Clin Transl Sci已检查 2 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:ROC 图;FIGURE 2:AI 判定为 other。 | PMID 41390988PMC12702135 | 2025-Dec | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 无 KM 图 |
| Real-world treatment patterns and subsequent treatment effectiveness following frontline brigatinib in the ALTA-1L trial.Future OncolAI 判定该论文不进入自动 KM 提取:This record is a retrospective chart-review study analyzing outcomes after frontline treatment in the ALTA-1L trial, not a new Phase III RCT. It reports real-world data on subsequent treatments, not the primary Phase III trial results. | PMID 41410381PMC12758242 | 2025-Dec | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Effects of rhEPO-Fc on chronic renal anemia in Chinese patients undergoing maintenance hemodialysis: a multicenter, randomized, open-label, and phase 3 study.Ren Fail已检查 1 张 PubMed Figure,均未识别为 KM 图:Figure 1:CONSORT/入组流程图。 | PMID 41481110PMC12777750 | 2025-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Safety and immunogenicity of a 3-dose schedule of a quadrivalent meningococcal tetanus toxoid conjugate vaccine administered concomitantly with routine pediatric vaccines to infants and toddlers: A descriptive randomized study.Hum Vaccin Immunother已检查 7 张 PubMed Figure,均未识别为 KM 图:Figure 1:研究设计图;Figure 2:AI 判定为 flow diagram;Figure 2:AI 判定为 flow diagram;Figure 3:AI 判定为 other;Figure 4:AI 判定为 other;另有 2 张未列出。 | PMID 41489614PMC12773564 | 2025-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Tislelizumab plus platinum and etoposide versus placebo plus platinum and etoposide as first-line treatment for extensive-stage small-cell lung cancer: patient-reported outcomes in the RATIONALE-312 trial.Curr Med Res Opin疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41614649无 PMCID | 2025-Dec | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Impact of combined hormonal contraceptives and metformin on metabolic syndrome in women with hyperandrogenic polycystic ovary syndrome and obesity: The COMET-PCOS randomized clinical trial.PLoS Med已检查 2 张 PubMed Figure,均未识别为 KM 图:Fig 1:AI 判定为 flow diagram;Fig 2:AI 判定为 other。 | PMID 41359669PMC12697981 | 2025-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Efficacy of Risankizumab across distinct PsA phenotypes identified with machine learning analytics using data from biologic DMARD-Naïve patients in two phase 3 clinical trials.Arthritis Res Ther已检查 3 张 PMC Figure,均未识别为 KM 图:Fig. 1:CONSORT/入组流程图;Fig. 2:AI 判定为 other;Fig. 3:AI 判定为 other。 | PMID 41318485PMC12771703 | 2025-Nov-29 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Sustained improvements in spinal pain, morning stiffness, fatigue, sleep, physical function and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: 2-year results from two phase 3 studies.RMD Open已检查 8 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other;Figure 4:AI 判定为 other;Figure 5:AI 判定为 other;另有 3 张未列出。 | PMID 41314667PMC12706112 | 2025-Nov-28 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| A composite endpoint for systemic sclerosis-associated interstitial lung disease: association with mortality in two clinical trial cohorts.Respir Res疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 2 张 PMC Figure,均未识别为 KM 图:Fig. 1:非 KM 图;Fig. 2:非 KM 图。 | PMID 41316297PMC12661867 | 2025-Nov-28 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Challenging the concept of functional high-risk myeloma through transcriptional and genetic profiling.Blood | PMID 40834881PMC12824701 | 2025-Nov-27 | 0.75 | This is a secondary, biomarker-focused analysis from the Myeloma-XI trial, examining the prognostic value of risk stratification. While the underlying trial is a Phase III randomized trial with drug interventions and time-to-event endpoints, this specific report does not present the primary or key secondary efficacy results of a drug-containing intervention vs. control. It is a subgroup/biomarker analysis. | 已完成 |
| Early Withdrawal of Aspirin after PCI in Acute Coronary Syndromes.N Engl J Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40888723无 PMCID | 2025-Nov-27 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Modification of belantamab mafodotin dosing to balance efficacy and tolerability in the DREAMM-7 and DREAMM-8 trials.Blood Adv | PMID 40763276PMC12657289 | 2025-Nov-25 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Eltrombopag for Newly Diagnosed Pediatric Immune Thrombocytopenia Requiring Treatment: The PINES Randomized Clinical Trial.JAMA | PMID 41123939PMC12547676 | 2025-Nov-25 | 0.98 | 未发现恶性肿瘤人群证据。 | 已完成 |
| Apatinib plus ifosfamide and etoposide versus ifosfamide and etoposide in patients with advanced osteosarcomas (OAIE/PKUPH-sarcoma 11): a randomized phase II study.Nat CommunAI 判定该论文不进入自动 KM 提取:This is a phase II randomized controlled trial, not a phase III trial. | PMID 41290609PMC12647724 | 2025-Nov-25 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 无 KM 图 |
| [Neoadjuvant chemoradiotherapy followed by active surveillance versus standard surgery for oesophageal cancer (SANO-trial): a phase 3 multicentre stepped-wedge cluster-randomised noninferiority trial].Ned Tijdschr Geneeskd疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41725589无 PMCID | 2025-Nov-25 | 0.95 | The record describes a randomized Phase III trial with a primary time-to-event endpoint (OS) and reports results. However, the intervention under investigation is a management strategy (active surveillance) versus standard surgery following neoadjuvant chemoradiotherapy. The eligibility criterion of a 'drug-containing intervention' is not met, as the trial does not randomize patients to different drug regimens. | 无 KM 图 |
| Safety and efficacy of pimavanserin in patients with Lewy body dementia experiencing dementia-related psychosis in the HARMONY study.BMC Neurol | PMID 41286676PMC12642364 | 2025-Nov-24 | 0.98 | 未发现恶性肿瘤人群证据。 | 已完成 |
| Paclitaxel-Coated Balloon for the Treatment of Small Vessel In-Stent Restenosis: A Subgroup Analysis of the AGENT IDE Randomized Trial.JACC Cardiovasc IntervPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41297981无 PMCID | 2025-Nov-24 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Daily Cigarette Abstinence and Smoking Rate With Varenicline: Relationships With Treatment, Craving, and Affect During the First Week of the Quit Attempt.Nicotine Tob Res已检查 2 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Figure 2:AI 判定为 other。 | PMID 40358028PMC12641181 | 2025-Nov-23 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Long-term tolerability and effectiveness of eptinezumab in Japanese adults with chronic migraine: results of the 60-week open-label SUNSET trial.J Headache Pain入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 41275111PMC12659320 | 2025-Nov-22 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Long-term efficacy of migalastat in females with Fabry disease.J Med Genet入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 40897525PMC12703307 | 2025-Nov-21 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |